What Detection Options Exist?
While PSA is commonly used as a screening tool, the PSA test cannot tell which prostate cancers can be safely left alone and which need aggressive treatment. It is therefore important to understand the difference between aggressive or clinically insignificant prostate cancer.
The gold standard for detecting Prostate Cancer is transrectal ultrasound (TRUS) guided prostate biopsy, an outpatient procedure that takes 15-30 minutes. While reasonably well tolerated in most men, about 40% of prostate biopsies can be associated with discomfort and complications, such as bleeding, infection, urinary incontinence, and sexual dysfunction.
It is established that 70-80% of prostate biopsies show no cancer or clinically insignificant slow growing cancers. Men diagnosed with prostate cancer can find out by taking a simple, non-invasive urine test that will tell them their risk (low vs. high) of having aggressive clinically significant prostate cancer.
What is the difference between slow-growing and aggressive prostate cancer?
There is a big difference between slow-growing (clinically insignificant or indolent) and aggressive (clinically significant) prostate cancer. The PSA Test has no way of differentiating these two types of prostate cancer.
- Slow-growing prostate cancer can be present in the body and never give rise to symptoms or lead to death during an individual’s lifetime
- Aggressive prostate cancer may grow quickly and have the ability to metastasize and spread to other parts of the body. These aggressive prostate cancers, if caught early can potentially save lives.
The result of The ExoDx Prostate Test can help a man understand his risk of having an aggressive prostate cancer.
Learn more about Prostate Cancer
DISCLAIMER: NOTHING IN THIS WEBSITE SHOULD BE CONSTITUTED AS GIVING MEDICAL ADVICE. PLEASE SPEAK WITH YOUR DOCTOR ABOUT YOUR SPECIFIC MEDICAL CONDITIONS, MEDICAL HISTORY AND RISK FACTORS FOR PROSTATE CANCER.